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C-reactive protein  (CRP) 1 was  discovered 50 years ago  (1)  by its ability to form 
insoluble precipitates with pneumococcal C polysaccharide (PnC). This precipitation 
reaction was subsequently found to be dependent on the presence of Ca  ++  (2)  and 
inhibitable by various phosphate monoesters (3).  After the demonstration that PnC 
is a ribitol teichoic acid cell-wall polymer (4) comprising choline phosphate (5) in its 
repeating structure, it was shown (6) that phosphocholine was a more potent inhibitor 
of the CRP-PnC precipitation reaction than other phosphate monoesters. Equilibrium 
dialysis experiments indicated that  in the presence of Ca  ++, CRP could bind phos- 
phocholine with an association constant of 1.6  ×  105 M -~ at  15°C  (7).  Each of the 
five, noncovalent subunits of CRP was found to have one binding site for phospho- 
choline. 
Similarly  to  CRP,  the  antigen-binding  murine  myeloma protein  $63  (a,K) was 
discovered by Cohn (8) by its ability to precipitate with PnC. A number of additional 
murine myeloma proteins precipitating with  PnC were subsequently described  (re- 
viewed in  [9]).  Inhibition studies  (10)  indicated  that  phosphocholine was the main 
determinant group for this precipitation reaction and direct-binding experiments (11) 
determined association constants varying between  1.6 ×  104 M -1 and 2.4 ×  105 M-' 
for the binding of phosphocholine to individual myeloma proteins. X-ray diffraction 
data on the Fab fragment of one phosphocholine-binding myeloma protein (PCBMP), 
McPC 603 (12) indicated that the hapten-binding site was formed by the first, second, 
and third hypervariable regions of the heavy chain (H1, H2, and H3, respectively) and 
by the first and third hypervariable regions of the light chain (L1 and L3, respectively). 
The main interactions between phosphocholine and the immunoglobulin-combining 
site are electrostatic and are mediated through residues in H1 and Hz (13). In addition, 
a  computer search of all available variable  (V)  region sequences  (14)  revealed that 
the H~ region sequence Phe32-Tyr33-Met~4-Glu35, which contains two contacting amino 
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acids  (Tyraa  and  Gluas),  is  unique  to  PCBMP.  It  is  of  further  interest  that  the 
corresponding tetrapeptide  from the  Ha of a  human  IgM PCBMP,  Fr,  is Phe-Tyr- 
Met-Asp (15). 
In contrast  to PCBMP,  the structure of the phosphocholine-binding  site of CRP 
has not been determined, even though the primary structure has been elucidated (16). 
Weak homologies between  the NHz-terminal amino acid sequence of CRP and the 
CHa domain of IgG were noted  (17)  but  their significance was disputed  when  the 
complete amino acid sequence of CRP was used for the comparison (16).  However, 
recently Young and Williams (18)  pointed out that despite the lack of strong overall 
sequence homologies between IgG and CRP, there are regions in the primary sequence 
of CRP that resemble the Hx and H2 regions of murine PCBMP and that the main 
contacting amino acids of the PCBMP  hapten-binding site appear to be present  in 
CRP.  These  authors  suggested  that  the  phosphocholine-binding  sites of CRP  and 
PCBMP may have common structural elements. In this study, such common structural 
elements were sought  by using monoclonal  antibodies  with  specificity for idiotypic 
determinants on the PCBMP  7N-hexyloctadecane plasma cell (HOPC) HOPC 8. 
Materials and Methods 
Reagents and Chromatographic Media.  Sephadex G-25 and Sepharose 4B were obtained from 
Pharmacia Fine Chemicals, Piscataway, N. J.; microgranular DEAE-cellulose  (Whatman DE- 
52) from H. Reeve Angel, Clifton, N. J.; electrophoresis grade acrylamide, N,N'-methylene-bis- 
acrylamide, sodium dodecyl sulfate (SDS), and ammonium persulfate from Bio-Rad Labora- 
•  .  •  125  tories,  Richmond, Cahf., career-free Na[  I] from Amersham Corp., Arlington Heights, Ill.; 
lactoperoxidase from Worthington, Biochemical Corp., Freehold,  N. J.; phosphocholine chlo- 
ride, calcium salt, and bovine serum albumin (BSA) from Sigma Chemical Co., St. Louis, Mo.; 
dinonylphthalate from ICN K & K Laboratories, Inc., Plainview,  N. Y.; and dibutylphthalate 
from Fisher Scientific Co., Pittsburgh, Pa. 
Phosphocholine was coupled to Sepharose as described by Chesebro and Metzger (19). Para- 
diazonium phosphocholine, a gift from Dr. D. Ewert, University of Alabama in Birmingham, 
Birmingham, Ala., was used to couple phosphocholine to keyhole limpet hemocyanin (KLH) 
(Calbiochem-Behring Corp., American Hoechst Corp., San Diego, Calif.). 
Purification and Radioiodination of CRP and HOPC 8.  Human CRP was purified from ascitic 
fluid by a previously described method (20), based on the Ca++-dependent affinity of CRP for 
phosphocholine. The protein was judged  pure by eleetrophoresis  on 5-20% polyacrylamide 
gradient  slab  gels  (21) containing  0.1% SDS.  Purified  CRP  was  labeled  with  a25I by the 
lactoperoxidase method of Marchalonis (22). The radioiodination mixture was then applied on 
a 3-ml phosphocholine-Sepharose 4B column and equilibrated in 0.1 M borate-buffered saline, 
pH 8.5,  containing  2 mM CaCI2. The column was washed with  the same buffer until  the 
radioactivity of the effluent was negligible.  Bound 125I-CRP was then eluted with the same 
buffer, containing 2 mM EDTA instead of CaCI2. The specific radioactivity of x2SI-CRP varied 
between  0.6  and  0.9  ttCi/~g.  More  than  98%  of the  radioactivity  was  protein  bound,  as 
determined by trichloroacetic acid (TCA~ precipitation. 
The mouse PCBMP HOPC 8 (a,~¢) (23) was purified from ascites fluid of mice bearing the 
myeloma HOPC  8  by  methods  described  by Chesebro  and  Metzger  (19). HOPC  8  was 
radioiodinated with ~2sI by the lactoperoxidase method (22) in the presence of a 20-fold molar 
excess of phosphocholine to protect the binding site. 12SI-HOPC 8 was separated from free 125I 
and phosphocholine by gel filtration on a 0.5- ×  50-cm  Sephadex G-25 column, followed by 
extensive dialysis against 0.01 M Tris-HCl, 0.15 M NaCI, pH 7.2. The specific radioactivity of 
12SI-HOPC 8 varied between  1 and 3 ttCi/~g. More than 97% of the radioactivity was TCA- 
precipitable. 
Monoclonal Anti-ldiotypic Antibodies (MAB).  Monoclonal antibodies reactive with idiotypic 
determinants expressed  by HOPC-8 were prepared by immunizing A/J mice with purified 
HOPC-8 myeloma protein and then fusing lymph node cells from these mice with the myeloma 1606  CROSS-REACTIVITY  BETWEEN C-REACTIVE  PROTEIN AND  HOPC  8 
P3-NS1/1-Ag4-1 (24). The details of preparation, purification, specificity analysis, and biolog- 
ical activities of these MAB have been described (25, 26). Briefly, the MAB AB 1-2 and GB4-10 
were of 71,r class, and reacted with HOPC 8 and TEPC 15 but no other murine PCBMP, and 
both reacted with an idiotope that was dependent on light and heavy chain association for 
expression. Although these antibodies are very similar, detailed analysis has revealed that they 
differ slightly in their fine specifieities. 2 MAB, EB3-7  (Tx,K) which reacted with an idiotypic 
determinant expressed by J558 (a,~,) an otl---~3 dextran-binding mouse myeloma protein was 
used in experiments as a control antibody. 
PnC.  PnC was isolated from rough Streptococcus pneumoniae, strain R36A (American Type 
Culture Collection, Rockville, Md.), as described by Liu and Gotschlich (27), except that the 
final enzymatic digestion step was omitted. 
Coupling of PnC to Sheep ETythrocytes.  PnC was  coupled to sheep  erythrocytes  (E)  by the 
chromium chloride method of Cosenza et al. (28): equal volumes of E (50% vol:vol), PnC (31- 
250/~g/ml), and chromium chloride (1  mg/ml) in 0.01  M  Tris-HC1, 0.15  M  NaCI, pH  7.2, 
were mixed and incubated at room temperature for 4 min. The sensitized erythrocytes (E-PnC) 
were washed three times with, and resuspended in the same buffer at a final concentration of 
5  ×  10  s cells/ml. Control E  were  prepared  by omitting PnC from  the chromium chloride 
reaction mixture. 
Assays for Binding and Inhibition of Binding of teSI-CRP and I~I-HOPC 8 to E-PnC.  Binding and 
inhibition assays were performed in 0.01 M Tris-HC1, 0.15 M NaCI buffer, pH 7.2, containing 
either 2.5 mM Ca  ++ or 1 mM EDTA, as indicated. In a typical binding experiment, E-PnC (5 
×  10S/ml) sensitized with increasing amounts of PnC were mixed with 50/~1 of 125I-CRP (1.8 
/zg/ml) or 125I-HOPC 8 (2.6 #g/ml). Controls consisted of mixtures of the radiolabeled proteins 
and  nonsensitized, chromium  chloride-treated  E.  The  mixtures  were  incubated at  room 
temperature for 30 min with occasional shaking. To separate free from cell-bound protein, the 
cells were centrifuged into an oil phase (29). 30-p,1 aliquots from each reaction mixture were 
layered on top of 300 #1  of a  mixture of dibutyl:dinonyl phthalate  (2:1;  vol:vol) in 400-~1 
conical polypropylene tubes. Centrifugation was carried out for 90 s at 6,500 g in an Eppendorf 
microcentrifuge (Brinkmann Instruments, Inc., Westbury, N.  Y.). The aqueous phase along 
with three-fourths of the oil mixture were removed, the tubes were cut just above the cell pellet, 
and the tips containing the cells were counted in a gamma counter to assess the amount of cell- 
bound protein. 
For inhibition experiments, E-PnC sensitized with 31/~g PnC/5 ×  l0  s E were utilized. The 
reaction mixtures consisted of 50/11 E-PnC (5 ×  10S/ml),  25/tl 12SI-CRP (3.6/~g/ml) or 25/xl 
:2SI-HOPC 8 (5.3/xg/ml), and 25 #1 of inhibitor at various concentrations. After incubation at 
room temperature for 30 rain, the amount of cell-bound radiolabeled protein was determined 
as  described above.  Percent  inhibition was  calculated from  a  control mixture lacking the 
inhibitor. 
Binding and Inhibition of Binding of tzSI-CRP and teSI-HOPC 8 to MAB.  Solid-phase assays were 
utilized for these studies. Polystyrene microwells (Removawell strips; Dynatech Laboratories, 
Inc., Dynatech Corp., Alexandria, Va.) were incubated with 300/tl of MAB solution (0.4-26 
~g/ml) in 0.01 M Tris-HCl~ 0.15 M NaCI buffer, pH 7.2, for 30 min at room temperature. The 
fluid was aspirated, the microwells washed with buffer, and incubated with 300/LI of a  10 mg/ 
ml solution of BSA in the same buffer to block remaining protein-binding  sites. After a 30-min 
incubation at room temperature, the microwells were washed three times with buffer and used 
immediately. Control microwells were prepared by omitting the initial incubation step with 
MAB. 
For binding studies,  MAB-coated and BSA-coated mierowells (controls)  were  incubated 
overnight at 4°C with 300 ~1 of lzSI-CRP (0.36/~g/ml) or of x2SI-HOPC 8 (0.17 p.g/ml) in buffer 
containing either 2.5  mM Ca  ++  or  1 mM  EDTA. The fluid was  aspirated,  the microwells 
washed three times with the appropriate buffer, and counted in a gamma counter to assess the 
amount of bound, radiolabeled protein.  Experimental values were corrected  for  the  small 
amount of radioactivity bound to control BSA-coated tubes. 
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For inhibition experiments, microwells coated with an amount MAB calculated to result in 
-30% binding of the 125I-CRP or 12bI-HOPC 8 offered were used. Increasing concentrations of 
the inhibitor tested dissolved in 0.01  M  Tris-HCl, 0.15  M  NaCl, pH 7.2, containing 2.5 mM 
Ca  ++ or 1 mM EDTA were added to the microwells, followed by 25/~l of 12SI-CRP (4.4 #g/ml) 
or 25 pl 12~I-HOPC 8 (2/xg/ml). After overnight incubation at 4°C, the fluid was aspirated, the 
microwells washed three times with buffer and the amount of bound radioactivity determined. 
Percent inhibition was calculated from a control lacking inhibitor after correcting all experi- 
mental  values for the small amount of radioactivity bound nonspecifically to control, BSA- 
coated microwells. 
Protein Determinations.  Concentrations of purified proteins were determined  spectrophoto- 
.....  EI%  metrically at  280 nm  using an extmcuon coeffioent (lcm)  of 19.5 CRP  (30) and  15.0 for 
HOPC 8. For calculating molar concentrations, the molecular weight of the phosphocholine- 
binding subunit of each protein was utilized--21,000 for the noncovalent subunit of CRP (16) 
and 75,000  for the heavy-light chain monomer of HOPC 8 (31). 
Results 
As  expected,  both  125I-CRP  and  125I-HOPC  8  bound  equally  well  to  E-PnC  in 
buffer  containing  2.5  mM  Ca  ++  (Fig.  1).  On  a  mole  per  mole  basis,  equimolar 
amounts  of pentameric  CRP  and  7S  monomer  of HOPC  8  bound  to  the  E-PnC 
throughout  the  linear  portion  of the  dose-response  curves.  As  shown,  under  the 
experimental  conditions used,  neither protein bound to control, chromium chloride- 
treated E. When this experiment was repeated using buffer containing  1 mM EDTA 
instead  of Ca  ++, the binding curve for 125I-HOPC 8  was identical  to that  shown  in 
Fig.  1, whereas the binding of 125I-CRP was completely abolished. 
Binding of either radiolabeled protein to E-PnC could be inhibited by micromolar 
concentrations  of phosphocholine  (Fig.  2).  This  is  in  agreement  with  previous  data 
demonstrating that phosphocholine is a potent inhibitor of the precipitation reactions 
between  either CRP  (6)  or HOPC  8  (10,  23)  and PnC.  Finally, the results of cross- 
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Fic.  3.  Inhibition  of binding of 12SI-CRP (A) and 12SI-HOPC 8 (B)  to E-PnC by cold CRP and 
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inhibition experiments between HOPC 8 and CRP are shown in Fig. 3.50% inhibition 
of  binding  of  I~SI-HOPC  8  to  E-PnC  required  equimolar  concentrations  of cold 
HOPC  8  or CRP.  On the other hand, 50%  inhibition of 125I-CRP binding required 
an eightfold greater concentration of HOPC 8 than of CRP. 
The  findings  described  above  and  the  observation  by  Young  and  Williams  (18) 
that certain regions of the CRP amino acid sequence are homologous to the first two 
hypervariable regions of the heavy chain of PCBMP,  led us to examine the possible 
interaction  between  CRP  and  GB4-10,  a  monoclonal antibody  with  specificity  for 
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micromolar concentrations could inhibit the binding of lzSI-HOPC 8 to E-PnC, and 
that at 30- to 50-fold higher concentrations, it could also partially inhibit the binding 
of 12SI-CRP to the sensitized cells. This apparent interaction between CRP and GB4- 
10  was  further  explored  by  direct-binding  experiments  using  a  solid-phase  assay 
system. Fig. 4 illustrates a representative binding experiment. Inspection of the curves 
indicates that in the presence of Ca  ++, binding of I~SI-HOPC 8 was observed when as 
little as 0.8 #g of GB4-10/1  ml were used to coat the microwells. Binding of ~50% of 
the 125I-HOPC 8 offered required  1.6 #g ofGB4-10/l ml. On the other hand, binding 
of 125I-CRP was  not  observed  until  6  #g GB4-10/ml  were  used  and  50%  binding 
required  12 #g/ml. In the presence of I mM EDTA, the binding of 125I-CRP to GB4- 
10 was completely inhibited,  whereas the binding of a25I-HOPC 8  was not  affected 
(Fig. 4). Similar results were obtained with a second independent anti-HOPC 8 MAB, 
AB1-2. AB1-2 was prepared similarly to GB4-10, but it differs from the latter in fine 
specificity. Again, binding of 125I-CRP was Ca++-dependent, whereas no Ca  ++ require- 
ment was evident for 125I-HOPC 8. Finally, as a control a third unrelated MAB, EB3- 
7, was used in a  similar experiment. EB3-7 has specificity for idiotypic determinants 
on  J558,  an  al--*3  dextran-binding  murine  myeloma  protein  (a,~).  Neither  125I- 
HOPC 8 nor 12~I-CRP bound to microwells coated with ~--30 #g/ml of EB3-7 either 
in the presence or absence of Ca  ++. 
Binding of either x25I-CRP or 125I-HOPC 8 to GB4-10 could be inhibited by similar 
concentrations  of KLH-linked  phosphocholine  (KLH-PC)  (Fig.  5).  However,  free 
phosphocholine inhibited only the binding of 125I-CRP, although it failed to inhibit 
that  of lzSI-HOPC 8  at  concentrations  up  to 0.45  raM.  Finally,  in  the  presence of 
Ca  ++, the binding of 125I-HOPC 8 to GB4-10 could be inhibited by cold HOPC 8 as 
well as by a  50-fold higher molar concentration of cold CRP (Fig. 6). Substitution of 
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Fro.  6.  Inhibition of binding of 12sI-HOPC 8 to immobilized GB4-10 by cold HOPC 8 and CRP 
in the presence of 2.5 mM Ca  ++ or 1 mM EDTA. 
EDTA  for Ca  ++  abolished  the  inhibitory  ability  of CRP  without  affecting  that  of 
HOPC  8. The binding of 12SI-CRP  to GB4-I0  could be inhibited  by cold CRP but 
not by HOPC 8 at the highest concentration tested. However, it should be noted that 
this  last  experiment  was  technically  difficult  because  the  concentration  of GB4-10 JOHN  E.  VOLANAKIS  AND JOHN  F.  KEARNEY  1611 
used to coat the tubes was ~ 10-fold higher than that used for binding of x25I-HOPC 
8. 
Discussion 
The human acute-phase protein CRP and the murine PCBMP HOPC 8 (a,K) share 
a common binding specificity for phosphocholine residues of PnC (6, 10). In addition, 
CRP and HOPC 8 exhibit similar association constants for the free hapten phospho- 
choline:  1.6 ×  105 M -1 and 2.4 ×  105 M -x, respectively (7,  11). Although no direct 
comparison has been made, the two proteins should not be expected to have identical 
fine-binding specificities. Binding of CRP but not of PCBMP to PnC can be inhibited 
by phosphate monoesters, whereas choline inhibits the binding of PCBMP but not of 
CRP.  A  further  essential  difference between  the  binding  speeificities of the  two 
proteins  is  the requirement of Ca  ++  for CRP.  Despite these differences, under the 
experimental  conditions used  in  this  study, the  two proteins  were  found  to  bind 
equally well to E-PnC and to require equimolar amounts of phosphocholine for 50% 
inhibition (Figs.  1 and 2). In addition, cross-inhibition experiments (Fig. 3) indicated 
that equimolar concentrations of HOPC 8 and CRP were required for 50% inhibition 
of binding of 125I-HOPC 8 to E-PnC, further emphasizing the similarities between the 
two proteins in terms of binding specificity and affinity. On the other hand, in the 
converse  experiment,  eightfold  more  HOPC  8  than  CRP  was  required  for  50% 
inhibition of binding of x25I-CRP.  This finding could not be  readily attributed to 
differences in affinity or fine specificity of the two proteins.  It could be explained 
though by previous data  (32) indicating that CRP may have a  secondary binding 
specificity for N-acetyl-galactosamine residues of PnC. 
The overall  similarity in  binding specificity and  affinity between HOPC  8  and 
CRP raised the possibility of structural similarities in their phosphocholine-binding 
sites. Such structural homology was previously suggested by Young and Williams (18) 
who pointed out that certain regions in the primary structure of  CRP bear resemblance 
to  Ha  and  H2  of PCBMP.  Monoclonal  antibodies  with  specificity  for  idiotypic 
determinants  associated with  the  variable  regions  of PCBMP  should  be  sensitive 
probes  for  such  structural  homologies  because  idiotypic  determinants  are  found 
exclusively on the FV fragment of immunoglobulins (33) and may be associated with 
antigen-binding  sites  (34,  35).  In  most  strains  of mice,  the  anti-phosphocholine 
response  is  dominated by  a  restricted  set  of antibodies  defined by  the TEPC  15 
idiotype  (36),  and  anti-idiotypic sera  to  TEPC  15  have  been  used  extensively in 
genetic and cellular studies of the immune response to phosphocholine. An idiotypic 
cross-reactivity between a human phosphocholine-binding IgM protein and a murine 
PCBMP, MOPC  167 has also been reported (37). Both MAB used in this study were 
raised against  HOPC  8  and recognized an idiotope dependent on  H  and L  chain 
association  for expression. This  idiotope was  not  present  in other PCBMP  tested, 
MOPC  167, M511, and W 3207, which have amino acid sequence differences from 
HOPC 8 in the VH and VL regions and are negative for the TEPC  15 idiotype (9). 
Preliminary experiments indicated that GB4-10 could inhibit the binding of 125I- 
CRP to E-PnC. However, compared with 125I-HOPC  8, much higher concentrations 
of GB4-10 were required and only partial inhibition was observed. This finding could 
perhaps be explained by the previously mentioned secondary-binding specificity of 
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specificity of the interaction between CRP and GB4-10. The direct-binding experi- 
ments (Fig. 4) clearly demonstrated the specificity of the interaction between 125I-CRP 
and  the  anti-HOPC  8  MAB.  First,  no binding of 125I-CRP  to EB3-7 an  unrelated 
MAB, was observed. Second, at the highest concentration of GB4-10 used, 66% of the 
125I-CRP offered bound to the immobilized MAB. This makes it highly unlikely that 
contaminants in the CRP preparation, such as anti-phosphocholine antibodies, were 
responsible for the observed binding. Third, EDTA completely inhibited the binding 
of ~25I-CRP to either GB4-10 or AB 1-2 without affecting the binding of ~2SI-HOPC  8. 
A Ca  ++ requirement was observed not only for the binding of 12~I-CRP to GB4-10 
and AB 1-2, but also for the inhibition of binding of 12~I-HOPC 8 to GB4-10 by CRP. 
The Ca  ++ dependence of these interactions might be relevant to the role of this anion 
in the binding of CRP to phosphocholine. CRP has been shown to bind Ca  ++ with an 
association constant of 1.3 ×  10  4 M -1 at 25°C and a valence of one to two per subunit 
(3). The exact role of Ca  ++ in the CRP-phosphocholine interaction is not known, but 
it has been suggested (3) that it might directly participate in binding the phosphate 
group. Our present data show that the expression of antigenic determinants of CRP, 
cross-reacting with idiotypic determinants on HOPC 8, depends on Ca  ÷+. Further- 
more, these determinants are apparently intimately associated with the phosphocho- 
line-binding  site,  as  indicated  by  the  hapten-inhibition  experiments  (Fig.  5).  It 
therefore appears,  that  Ca  ++  acts  as an allosteric effector of CRP,  essential  for the 
proper conformation of its phosphocholine-binding site.  Evidence for Ca++-induced 
conformational changes of CRP has been previously provided by circular dichroism 
studies (18). 
The finding that antigenic determinants on CRP, a nonimmunoglobulin molecule, 
cross-react  with  idiotypic determinants  might  be  important  in  understanding  the 
evolutionary origin of antibody-combining sites. 
Summary 
Binding of human  125I-C-reactive protein  (CRP)  to sheep erythrocytes sensitized 
with pneumococcal C  polysaccharide (E-PnC) was found to be Ca÷+-dependent and 
inhibitable by phosphocholine, CRP,  and  HOPC 8.  Binding of 125I-HOPC 8 to E- 
PnC was  Ca++-independent  but  could also be inhibited by phosphocholine, CRP, 
and  HOPC  8.  Thus,  CRP  and  HOPC  8,  despite a  differential Ca ++  requirement, 
share a common binding specificity for phosphocholine. A monoclonal anti-idiotypic 
antibody (MAB), GB4-10, prepared in A/J mice immunized with BALB/c HOPC 8 
inhibited the binding of both 125I-CRP and 12SI-HOPC  8 to E-PnC. In addition, both 
proteins bound to GB4-10 immobilized on polysterene tubes. Interestingly, binding of 
12~I-CRP to GB4-10 required Ca ++.  Similar results were also obtained with another 
MAB  (AB1-2)  prepared  similarly  to  GB4-10, whereas  neither  protein  bound  to  a 
control  MAB  (EB3-7)  against  an  al---~3  dextran-binding  myeioma  protein, J558. 
Binding of 125I-HOPC 8  to GB4-10 could be inhibited by HOPC 8, keyhole limpet 
hemocyanin-phosphocholine but not phosphocholine, and in the presence of Ca ++ by 
CRP. These data indicate that CRP bears antigenic determinants cross-reacting with 
certain idiotypic determinants on HOPC 8.  They also suggest that Ca  ++ acts as an 
allosteric effector, perhaps stabilizing the phosphocholine-binding site of CRP. JOHN  E.  VOLANAKIS AND JOHN  F.  KEARNEY  1613 
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